Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

Baqsimi (glucagon) may be safe to use while pregnant ... If you’re currently breastfeeding or planning to do so, it’s important to understand the effects that Baqsimi could have on you or ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

GLP-1 agonists mimic the natural hormone glucagon-like peptide-1 (GLP-1), produced ... this paid post belong solely to the contributor and do not represent the views of Lee Enterprises. The publisher ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...